Armonair Respiclick is a drug owned by Teva Pharmaceutical Industries Ltd. It is protected by 35 US drug patents filed from 2017 to 2024. Out of these, 26 drug patents are active and 9 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 20, 2040. Details of Armonair Respiclick's patents and their expiration are given in the table below.

A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Armonair Respiclick's patents.

Latest Legal Activities on Armonair Respiclick's Patents

Given below is the list of recent legal activities going on the following patents of Armonair Respiclick.

Activity	Date	Patent Number
Critical Events This Week
Payment of Maintenance Fee, 8th Year, Large Entity	21 Mar, 2024	US9463288
Payment of Maintenance Fee, 4th Year, Large Entity	21 Feb, 2024	US10765820
Expire Patent Critical	02 Oct, 2023	US8006690
Payment of Maintenance Fee, 4th Year, Large Entity	20 Jul, 2023	US10561808
Payment of Maintenance Fee, 8th Year, Large Entity	23 May, 2023	US9216260
Maintenance Fee Reminder Mailed Critical	19 Apr, 2023	US8006690
Payment of Maintenance Fee, 8th Year, Large Entity	08 Sep, 2022	US8978966
Payment of Maintenance Fee, 4th Year, Large Entity	27 Jul, 2022	US10195375
Payment of Maintenance Fee, 4th Year, Large Entity	04 May, 2022	US10124131
Payment of Maintenance Fee, 4th Year, Large Entity	14 Jan, 2022	US10022510

While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Armonair Respiclick and ongoing litigations to help you estimate the early arrival of Armonair Respiclick generic.

Armonair Respiclick's Litigations

Armonair Respiclick been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Armonair Respiclick's patents.

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
Live updates
US10561808	October, 2018	Decision (20 Sep, 2019)	Declan Walsh et al.

FDA has granted some exclusivities to Armonair Respiclick. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Armonair Respiclick, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Armonair Respiclick.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Download Report

Several oppositions have been filed on Armonair Respiclick's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Armonair Respiclick's generic, the next section provides detailed information on ongoing and past EP oppositions related to Armonair Respiclick patents.

Armonair Respiclick's Oppositions Filed in EPO

Armonair Respiclick has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 03, 2009, by Vectura Delivery Devices Limited. This opposition was filed on patent number EP01948660A. Click below to reveal the latest opposition data.

Application	Filing Date	Opposition Party	Legal Status
Live updates
EP19155324A	Jun, 2021	Vectura Limited	Granted and Under Opposition
EP04782768A	Apr, 2015	AstraZeneca Pharma Poland Sp. z.o.o.	Revoked
EP01948660A	Aug, 2014	Hexal Aktiengesellschaft	Patent maintained as amended
EP04782768A	Nov, 2011	Vectura Limited	Revoked
EP04782768A	Nov, 2011	AstraZeneca AB	Revoked
EP01948660A	Sep, 2009	Vectura Delivery Devices Limited	Patent maintained as amended

US patents provide insights into the exclusivity only within the United States, but Armonair Respiclick is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Armonair Respiclick's family patents as well as insights into ongoing legal events on those patents.

Armonair Respiclick's Family Patents

Armonair Respiclick has patent protection in a total of 34 countries. It's US patent count contributes only to 16.4% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Armonair Respiclick.

Full family tree

Generic Launch

About Armonair Respiclick

Armonair Respiclick is a drug owned by Teva Pharmaceutical Industries Ltd. Armonair Respiclick uses Fluticasone Propionate as an active ingredient. Armonair Respiclick was launched by Teva Pharm in 2022.